Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.

ABSTRACT:

Importance

Although several cancer drugs receive US Food and Drug Administration (FDA) approval each month, it is unclear how many of these cancer drugs transform the treatment landscape significantly by tumor group. Specifically, it remains unclear how many of these newly approved cancer drugs displace the existing standard-of-care therapies for their indication vs being added to existing therapies.

Objective

To examine how many cancer drugs displace the standard-of-care therapies vs being added to existing therapy or filling breaks in systemic treatments in the metastatic setting, adjuvant setting, or maintenance setting.

Design, setting, and participants

Retrospective cross-sectional study using landmark trials leading to FDA approval of cancer drugs between May 1,

SUBMITTER: Benjamin DJ 

PROVIDER: S-EPMC8924721 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature